Abstract
Retention of participants for intervention and follow-up activities is critical in cancer chemoprevention trials. Little has been published about retention patterns and predictors of retention in prevention studies. The Carotene and Retinol Efficacy Trial (CARET) provides an opportunity to study retention of volunteer participants in a large, long-term clinical trial. Two pilot studies were conducted in different populations to test the feasibility of critical strategies for the long-term study. Thirteen percent of the asbestos-exposed workers and 18% of the smokers became inactive during the pilot study. Of those remaining active, all but 2% of asbestos-exposed workers pilot study participants and 5% of smokers pilot study participants chose to participate in the full-scale efficacy trial. Five baseline predictors of inactivity for the asbestos-exposed participants emerged: being non-White, being a current smoker, having a history of high blood pressure at baseline, reporting two or more increases in symptoms during the placebo run-in, and having higher baseline levels of negative mental health measures (i.e. anxiety, depression, and fatigue). The only significant predictor of inactivity for smoker pilot participants was reporting symptoms during the placebo run-in. The most frequently reported reasons for becoming inactive during the pilot studies were general health issues and problems and symptoms that were seen as specific to the CARET vitamins. These findings suggest areas that could be tested to optimize retention in clinical trials.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Meinert CL:Clinical Trials: Design, Conduct, and Analysis. New York: Oxford University Press, 1986.
Meichenbaum D, Turk DC:Facilitating Treatment Adherence: A Practitioner’s Guidebook. New York: Plenum Press 1987.
Shumaker SA, Schron EB, Ockene JK, et al:Handbook of Health Behavior Change. New York: Springer, 1990.
Omenn GS, Goodman GE, Thornquist M, et al: The β-Carotene and Retinol Efficacy Trial (CARET) for chemoprevention of lung cancer in high-risk populations: Smokers and asbestos-exposed workers.Cancer Research. 1994,54:2038S-2043S.
Omenn GS, Goodman GE, Thornquist M, et al: Effects of a combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease.New England Journal of Medicine. 1996,334:1150–1155.
Omenn G, Goodman G, Thornquist M, et al: Risk factors for lung cancer and for intervention effects in CARET, the beta-Carotene and Retinol Efficacy Trial.Journal of the National Cancer Institute. 1996,88:1550–1559.
Goodman GE, Omenn GS, Thornquist MD, et al: The Carotene and Retinol Efficacy Trial (CARET) to prevent lung cancer in high-risk populations: Pilot study with cigarette smokers.Cancer Epidemiology, Biomarkers and Prevention. 1993,2:389–396.
Omenn GS, Goodman GE, Thornquist MD, et al: The Carotene and Retinol Efficacy Trial (CARET) to prevent lung cancer in high-risk populations: Pilot study with asbestos-exposed workers.Cancer Epidemiology, Biomarkers and Prevention. 1993,2:381–387.
Mor V, Laliberte L, Morris JN, Wiemann M: The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting.Cancer. 1984,53:2002–2007.
Karnofsky DA, Buchenal JH: The clinical evaluation of chemotherapeutic agents in cancer. In MacLeod CM (ed),Evaluation of Chemotherapeutic Agents. New York: Columbia University Press, 1949, 191–205.
Author information
Authors and Affiliations
About this article
Cite this article
Bowen, D.J., Cartmel, B., Barnett, M. et al. Predictors of participant retention in two chemoprevention feasibility trials. ann. behav. med. 21, 210–215 (1999). https://doi.org/10.1007/BF02884835
Issue Date:
DOI: https://doi.org/10.1007/BF02884835